EIB funds Ebola vaccine development


Lends Bavarian Nordic €50m to accelerate Ebola project

The European Investment Bank (EIB) is lending €50m to Denmark-based biotechnology company Bavarian Nordic to accelerate its work in developing a vaccine against the Ebola virus. The decision showed that the bank backed 'investment where it is needed…in difficult or uncertain circumstances', claimed EIB President Werner Hoyer. The company started Phase 1 clinical trials this month.